Article

Increased expression of guanylate binding protein‐1 in lesional skin of patients with cutaneous lupus erythematosus

Division of Molecular and Experimental Surgery, University Medical Center Erlangen, Erlangen, Germany.
Experimental Dermatology (Impact Factor: 4.12). 02/2011; 20(2):102-6. DOI: 10.1111/j.1600-0625.2010.01160.x
Source: PubMed

ABSTRACT The large GTPase human guanylate binding protein-1 (GBP-1) is a key mediator of angiostatic effects of inflammation and is induced by interferon (IFN)-α and IFN-γ in endothelial cells (ECs). The aim of this study was to investigate whether GBP-1 is a marker of skin lesions in patients with cutaneous lupus erythematosus (CLE). Western blotting revealed that GBP-1 was in vitro induced by IFN-α and -γ in primary keratinocytes obtained from healthy controls. Moreover, we found that this protein was expressed by keratinocytes and ECs in primary and ultraviolet (UV)-induced skin lesions from patients with various subtypes of CLE, when compared to non-lesional skin. No GBP-1 expression was noted in skin biopsy specimens 24 or 72 h after UV irradiation prior to lesion formation in patients with CLE or in healthy control specimens with or without UV irradiation. Initial findings suggest that GBP-1 is not expressed in other skin diseases with different inflammatory aetiology, such as atopic dermatitis. We conclude that GBP-1 expression is closely associated with skin lesions in patients with CLE, suggesting a contribution of GBP-1 in the pathogenesis of this disease.

Download full-text

Full-text

Available from: Joerg Wenzel, Jul 28, 2015
0 Followers
 · 
150 Views
  • Source
    • "In accord with the proposed mechanism, inhibitors of TLR7 and TLR9 signaling in a lupus-prone murine model of interface dermatitis attenuated the skin lesions [88]. Moreover, a recently identified IFNα-and γ-induced protein—the GTPase human guanylate binding protein- 1 (GBP-1)—is expressed by keratinocytes and endothelial cells in primary and ultraviolet-(UV-) induced skin lesions from patients with various subtypes of CLE compared to nonlesional skin [89]. It has also been recently demonstrated that the IFNα-inducible IFI16 protein—normally localized in the nucleus—translocates in the cytoplasm of affected skin cells from lupus patients and in UV irradiated keratinocytes—leading to generation of antibodies against the IFNα-inducible IFI16 recently detected in sera of lupus patients [90] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Growing evidence over the last few years suggests a central role of type I IFN pathway in the pathogenesis of systemic autoimmune disorders. Data from clinical and genetic studies in patients with systemic lupus erythematosus (SLE) and lupus-prone mouse models, indicates that the type I interferon system may play a pivotal role in the pathogenesis of several lupus and associated clinical features, such as nephritis, neuropsychiatric and cutaneous lupus, premature atherosclerosis as well as lupus-specific autoantibodies particularly against ribonucleoproteins. In the current paper, our aim is to summarize the latest findings supporting the association of type I IFN pathway with specific clinical manifestations in the setting of SLE providing insights on the potential use of type I IFN as a therapeutic target.
    BioMed Research International 11/2011; 2011:273907. DOI:10.1155/2011/273907 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical manifestations of cutaneous lupus erythematosus are diverse and different subtypes of the disease have been defined. It is characteristic for lupus skin inflammation that a significant activation of innate interferon pathways is observable. Endogenous molecules indicative for tissue damage (damage-associated molecular patterns [DAMPs]) show cytokine-like properties once released from intracellular compartments and these DAMPs have been shown to influence the course of inflammatory responses. Cytokines including TNF-αα and IL-1 family members significantly contribute to the chronic inflammatory phenotype and, in combination with DAMPs, impact on the activation of innate interferons. A better understanding of the deregulated cytokine network in cutaneous lupus erythematosus patients with distinct disease phenotypes and genetic backgrounds is of high importance and a prerequisite for recommending and developing more individualized therapeutic strategies.
    Expert Review of Dermatology 07/2011; 6(4):381-394. DOI:10.1586/edm.11.39
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Proinflammatory cytokines induce guanylate-binding protein 1 (GBP-1) protein expression in intestinal epithelial tissues. GBP-1 has been described as influencing a number of cellular processes important for epithelial homeostasis, including cell proliferation. However, many questions remain as to the role of GBP-1 in intestinal mucosal homeostasis. We therefore sought to investigate the function of proinflammatory cytokine-induced GBP-1 during intestinal epithelial cell proliferation. Through the use of complementary GBP-1 overexpression and small interfering RNA-mediated knockdown studies, we now show that GBP-1 acts to inhibit pro-mitogenic β-catenin/T cell factor (TCF) signaling. Interestingly, proinflammatory cytokine-induced GBP-1 was found to be a potent suppressor of β-catenin protein levels and β-catenin serine 552 phosphorylation. Neither glycogen synthase kinase 3β nor proteasomal inhibition alleviated GBP-1-mediated suppression of cell proliferation or β-catenin/TCF signaling, indicating a non-canonical mechanism of β-catenin inhibition. Together, these data show that cytokine-induced GBP-1 retards cell proliferation by forming a negative feedback loop that suppresses β-catenin/TCF signaling.
    Mucosal Immunology 06/2012; 5(6):681-90. DOI:10.1038/mi.2012.41 · 7.54 Impact Factor
Show more